item management s discussion and analysis of financial condition and results of operations 
the following discussion of the financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto included in item a of this annual report on form k 
overview impath was founded in and has become a leader in providing critical information essential for making medically optimal and cost effective cancer management decisions for individual cancer patients 
the company is focused exclusively on the analysis of cancer  combining advanced technologies and medical expertise to provide patient specific diagnostic  prognostic and treatment information to physicians involved in the treatment of cancer 
with expected medical cost increases attributable to the growth in the number of cancer patients and the high cost of new therapies  the company anticipates significant and growing demand for cancer management information 
impath has established its leadership and reputation through its extensive expertise  its integration of technological advances  its emphasis on customer service and education and the cost effectiveness of its services 
the company s revenues  which have increased an average of approximately annually since  have been derived from performing specialized cancer analyses for which impath typically bills various third party payors  such as private insurance plans  managed care plans and governmental programs eg  medicare  as well as hospitals and individual patients 
over the last few years  the company has experienced increased pressures on reimbursement and expects such pressures to cause reduced unit pricing for diagnostic and prognostic analyses in future periods 
despite those pressures  the company has experienced increasing average reimbursement trends due to changes in its services and payor mix and application of new technologies 
see risk factors reimbursement and business reimbursement 
the following table sets forth the percentages of total revenues represented by certain items reflected in the company s consolidated statements of operations 
the company s business generally has been unaffected by seasonality  except for slower growth in revenues during the third quarter of its fiscal year due to reduced summertime activity 
years ended december  total revenues operating expenses salaries and related costs selling  general and administrative total operating expenses operating income net income recent acquisitions impath has successfully completed the acquisition and integration of several complementary regional businesses which have added to the breadth and depth of its technological expertise and services 
in january  impath hdc  inc  a wholly owned subsidiary of the company  acquired a cancer testing facility from oncogenetics  inc oncogenetics  which expanded impath s business into new growth areas in oncology  such as molecular and cytogenetic testing for cancer 
in february  the company purchased certain assets of the oncology division of immunodiagnostic laboratories  inc immunodiagnostic 
in september  impath acquired certain assets of the gencare division of bio reference laboratories inc gencare  a new jersey based cancer laboratory specializing in tissue based testing and tumor marker analyses 
in october  impath purchased certain assets of aeron biotechnology  inc aeron  a california based cancer testing facility specializing in breast cancer prognostic analysis 
additionally  the company acquired aeron s tissue bank containing more than  analyzed cases  many of which have detailed historical registry data and corresponding outcomes information 
year ended december  compared with year ended december  the company s total revenues in and were million and million  respectively  representing an increase of million  or  in this growth was primarily due to a increase in case volume resulting from increased sales and marketing activities and to the successful integration of the company s acquisitions of certain assets of oncogenetics  immunodiagnostic  gencare and aeron 
in addition  revenue realization per case increased as a result of product mix changes towards cases which yield higher reimbursement rates and payor mix shifts away from direct hospital billing towards private insurance 
salaries and related costs in and were million and million  respectively  representing an increase of million  or  in this increase was primarily due to direct personnel costs associated with existing product case volume growth as well as the company s acquisitions during as a percentage of total revenues  salaries and related costs decreased to in from in selling  general and administrative expenses in and were million and million  respectively  representing an increase of million  or  in this increase was due to an increase in bad debt expense of approximately million associated with higher revenues  as well as a payor mix shift from direct hospital billings to private insurance resulting in higher revenues and patient co payments that generate higher bad debt 
the company also incurred million in additional selling  general and administrative expenses associated with the company s arizona based cancer cytogenetics testing facility which was acquired from oncogenetics in january in addition  the company incurred over million in incremental supply and courier costs due to increased volume and the logistics required to service the company s rapidly growing oncology office based business 
depreciation and amortization costs increased approximately  primarily due to additional capital expenditures  goodwill amortization associated with the company s acquisitions and amortization of third party development costs for the outcomes database 
the company also incurred higher travel related expenses and professional fees associated with expanded sales  marketing and investor relations activities 
as a percentage of total revenues  selling  general and administrative expenses decreased to in compared to in income from operations in and was million and million  respectively  representing an increase of million  or  in the figure reflects increased company operating margins from its core diagnostic and prognostic services 
as a percentage of total revenues  income from operations increased to in from in other income  net for and was  and million  respectively  representing a decrease of approximately  in this decrease was the result of lower investment returns resulting from the use of the company s cash and cash equivalents in order to fund the company s expansion and database development activities 
the tax provision for of approximately million reflects federal  state and local income tax expense 
the effective tax rate is consistent with the rate 
net income in and was million and million  respectively  representing an increase of million  or  in which was due to the factors described above 
year ended december  compared with year ended december  the company s total revenues in and were million and million  respectively  representing an increase of million  or  in this growth was primarily attributable to a increase in case volume resulting from increased sales and marketing activities 
in addition  revenue realization per case increased due to payor mix and product mix changes toward cases that carry a higher reimbursement rate 
salaries and related costs in and were million and million  respectively  representing an increase of million  or  in this increase was primarily attributable to a increase in personnel headcount associated with case volume growth as well as personnel costs incurred in connection with the company s expansion 
as a percentage of total revenues  salaries and related costs decreased to in from in selling  general and administrative expenses in and were million and million  respectively  representing an increase of million  or  in the primary component of this increase was an increase in bad debt expense of approximately  associated with increased revenues  specifically generated from third party billing 
third party revenues have historically had a higher bad debt rate than institutional revenues 
case volume growth necessitated an increase of  in laboratory supplies and consulting fees and a  increase in automobile and courier expenses 
in addition  rent expense and depreciation and amortization costs increased  and  respectively  due to the establishment of the company s california facility and the development of new clinical and billing operating systems 
additional depreciation costs also resulted from the company s expansion and database development activities 
the company also incurred an additional  in higher travel and marketing costs associated with its expanded sales  marketing and investor relations activities 
as a percentage of total revenues  selling  general and administrative expenses decreased to in from in income from operations in and was million and million  respectively  representing an increase of million  or  in the figure reflects the effect on operating income of increased revenue growth and a decrease in operating expenses as a percentage of revenue from in to in other income  net for and was million and  respectively  representing an increase of approximately million in the increase was the result of income generated from trading gains on marketable securities using the proceeds of the company s initial public offering of common stock in february  partially offset by increased interest expense due to additional capital lease obligations 
the tax provision for of approximately million reflects federal  state and local income tax expense 
for  the company utilized its remaining net operating losses and recorded deferred tax assets to the extent of taxes that it had expected to pay on estimated taxable earnings 
management believes that realization of such deferred tax assets was more likely than not 
as such  the company s annual effective tax rate for was zero 
as a result  net income in and was million and million  respectively  representing an increase of million  or  in as a percentage of total revenues  net income increased to in from in liquidity and capital resources since its inception  the company has raised approximately million of capital through the initial public offering of common stock and private placements of preferred stock  all of which was converted into common stock at the closing of the initial public offering in february the company s working capital and capital expenditure needs have increased and are expected to continue to increase as the company expands its existing facilities and pursues its growth strategy 
see business company strategy 
the company s cash and cash equivalent balances at december  and were approximately  and  respectively  representing a decrease of  in the company also had approximately million invested in a portfolio of investment grade fixed income securities at december  for  net cash generated from operating activities was approximately million 
this was the result of cash inflows from the sale of marketable trading securities of million and the company s net income  partially offset by increases in accounts receivable  net of allowance for bad debt provisions of million due to rapid sales growth 
the company also reduced its accounts payable and accrued expenses by  during  the company used approximately million of cash to fund its growth strategy through the acquisition of certain assets of oncogenetics  immunodiagnostic  gencare and aeron 
see recent acquisitions 
in addition  the company had capital expenditures of million during  primarily related to the development of the company s clinical and billing systems 
the company received approximately  during through the issuance of common stock upon the exercise of incentive stock options and warrants 
the company used approximately million to satisfy its capital lease obligations 
in november  the company renewed its line of credit at an aggregate amount of million 
borrowing under the line will bear interest at the prime rate 
the availability of a million replacement line of credit  which was approved in november and will bear interest at libor plus  is subject to the execution of such additional documentation as the lender may request 
as of december   the company had not drawn on the line of credit 
the company s growth strategy is anticipated to be financed through the net proceeds from a proposed underwritten public offering of  shares of its common stock  its current cash resources and existing third party credit facilities 
the company believes the combination of these sources will be sufficient to fund its operations and to satisfy the company s cash requirements for the next months and the foreseeable future 
there may be circumstances  however  that would accelerate the company s use of its liquid resources 
if this occurs  the company may  from time to time  incur additional indebtedness or issue  in public or private transactions  equity or debt securities 
however  there can be no assurance that suitable debt or equity financing will be available to the company 
impact of inflation and changing prices the impact of inflation and changing prices on the company has been primarily limited to salary  laboratory and operating supplies and rent increases and has not been material to date to the company s operations 
in the future  the company may not be able to raise the prices for its cases by an amount sufficient to cover the cost of inflation  although the company is responding to these concerns by attempting to increase the volume and adjust the product mix of its business 
year the company is in the final stages of the installation of newly developed clinical and billing information systems which address year issues 
the company does not expect the amounts required to be expended over the next three years in connection with year compliance issues to have a material effect on its financial position or results of operations 
item quantitative and qualitative disclosures about market risk 
not applicable 

